Key Health Developments: From Vaccine Trials to Drug Shortages

This summary compiles recent health news, including Eli Lilly's weight-loss drug being removed from the FDA's shortage list, Rwanda's upcoming vaccine trials for Marburg disease, and WuXi's potential sale due to US restrictions. Gilead Sciences issues royalty-free licenses to sell HIV drugs, and US CDC warns about online counterfeit prescriptions.

Eli Lilly's popular weight-loss and diabetes drugs have been taken off the FDA's shortage list, likely increasing pressure on firms selling cheaper compounded alternatives. Mounjaro and Zepbound were previously on the list due to supply issues.

Rwanda is set to begin vaccine trials for Marburg disease after battling its first outbreak. The virus has resulted in 11 deaths, with 36 cases reported so far, according to health ministry figures. WHO has indicated a high risk level in the region.

Meanwhile, Gilead Sciences plans to provide generic manufacturers licenses to sell its HIV prevention medication in 120 low-income countries. This initiative aims to address 70% of global HIV cases, aiding countries like Botswana and Kenya.

(With inputs from agencies.)